AU2019371457A1 - Anti-TIM-3 antibodies - Google Patents
Anti-TIM-3 antibodies Download PDFInfo
- Publication number
- AU2019371457A1 AU2019371457A1 AU2019371457A AU2019371457A AU2019371457A1 AU 2019371457 A1 AU2019371457 A1 AU 2019371457A1 AU 2019371457 A AU2019371457 A AU 2019371457A AU 2019371457 A AU2019371457 A AU 2019371457A AU 2019371457 A1 AU2019371457 A1 AU 2019371457A1
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- seq
- tim
- cell
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862754383P | 2018-11-01 | 2018-11-01 | |
| US62/754,383 | 2018-11-01 | ||
| PCT/US2019/059555 WO2020093023A1 (en) | 2018-11-01 | 2019-11-01 | Anti-tim-3 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019371457A1 true AU2019371457A1 (en) | 2021-05-20 |
Family
ID=69159931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019371457A Abandoned AU2019371457A1 (en) | 2018-11-01 | 2019-11-01 | Anti-TIM-3 antibodies |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220081480A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3873611A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022505925A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113272017A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019371457A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3117429A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL282707A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020093023A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7214440B2 (ja) * | 2018-11-01 | 2023-01-30 | 三菱重工エンジニアリング株式会社 | 検証処理装置、検証処理方法及びプログラム |
| JPWO2023286854A1 (cg-RX-API-DMAC7.html) * | 2021-07-16 | 2023-01-19 | ||
| TW202327649A (zh) * | 2021-09-15 | 2023-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Pvrig/tigit結合蛋白聯合免疫檢查點抑制劑用於治療癌症 |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| CN119654339A (zh) | 2022-07-01 | 2025-03-18 | 特兰斯吉恩股份有限公司 | 包含表面活性蛋白-d和tnfsf成员的融合蛋白 |
| WO2025202222A1 (en) | 2024-03-25 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells |
| WO2026059950A1 (en) * | 2024-09-10 | 2026-03-19 | Agilent Technologies, Inc. | Anti-human tim3 antibodies for in vitro diagnostics |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| DK1366067T3 (da) | 2001-03-07 | 2012-10-22 | Merck Patent Gmbh | Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| US8993524B2 (en) | 2010-03-05 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| PL3099717T3 (pl) | 2014-01-31 | 2019-10-31 | Novartis Ag | Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie |
| HRP20210977T1 (hr) | 2014-02-10 | 2021-09-17 | Merck Patent Gmbh | Ciljano inhibiranje tgf beta |
| AU2015340056A1 (en) * | 2014-10-27 | 2017-05-25 | Agency For Science, Technology And Research | Anti-TIM-3 antibodies |
| US20180153986A1 (en) * | 2015-04-24 | 2018-06-07 | The Brigham And Women's Hospital, Inc. | Interactions between ceacam and tim family members |
| US20180207273A1 (en) * | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| PT3370768T (pt) * | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| US20190248893A1 (en) * | 2016-07-14 | 2019-08-15 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| JOP20190013A1 (ar) * | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
| MA50677A (fr) * | 2016-11-01 | 2021-07-14 | Anaptysbio Inc | Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3) |
| TWI665216B (zh) * | 2016-12-29 | 2019-07-11 | 財團法人生物技術開發中心 | 抗人類tim-3抗體及其使用方法 |
| AU2018205401B2 (en) * | 2017-01-09 | 2025-01-02 | Tesaro, Inc. | Methods of treating cancer with anti-TIM-3 antibodies |
| CN110050000B (zh) | 2017-05-12 | 2022-07-26 | 苏州盛迪亚生物医药有限公司 | 含有TGF-β受体的融合蛋白及其医药用途 |
-
2019
- 2019-11-01 CA CA3117429A patent/CA3117429A1/en active Pending
- 2019-11-01 CN CN201980086657.5A patent/CN113272017A/zh active Pending
- 2019-11-01 WO PCT/US2019/059555 patent/WO2020093023A1/en not_active Ceased
- 2019-11-01 EP EP19835889.7A patent/EP3873611A1/en not_active Withdrawn
- 2019-11-01 AU AU2019371457A patent/AU2019371457A1/en not_active Abandoned
- 2019-11-01 JP JP2021523011A patent/JP2022505925A/ja active Pending
-
2021
- 2021-04-27 IL IL282707A patent/IL282707A/en unknown
- 2021-04-30 US US17/245,474 patent/US20220081480A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022505925A (ja) | 2022-01-14 |
| WO2020093023A1 (en) | 2020-05-07 |
| CN113272017A (zh) | 2021-08-17 |
| US20220081480A1 (en) | 2022-03-17 |
| IL282707A (en) | 2021-06-30 |
| EP3873611A1 (en) | 2021-09-08 |
| CA3117429A1 (en) | 2020-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230406935A1 (en) | Fc binding fragments comprising a pd-l1 antigen-binding site | |
| US20220081480A1 (en) | Anti-tim-3 antibodies | |
| CN112424229B (zh) | 结合cd137和ox40的抗体分子 | |
| AU2020363041B2 (en) | Antibodies against the poliovirus receptor (PVR) and uses thereof | |
| JP2021524268A (ja) | Pd−l1及びcd137に結合する抗体分子 | |
| US20220073616A1 (en) | Methods of administering anti-tim-3 antibodies | |
| KR20200083598A (ko) | 이뮤노글로불린-유사 전사체 3 (ilt3)에 대해 특이적인 항체 및 그의 용도 | |
| JP7689116B2 (ja) | Pd1およびvegfr2二重結合剤 | |
| KR20230158058A (ko) | 시알산-결합 ig-유사 렉틴 15에 특이적인 항체 및 이의 용도 | |
| HK40058527A (en) | Anti-tim-3 antibodies | |
| RU2826084C2 (ru) | МОЛЕКУЛЫ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ PD-L1 и CD137 | |
| KR20250154601A (ko) | Nkg2a와 pd-l1에 결합하는 작용제 및 이의 용도 | |
| HK40059550A (en) | Methods of administering anti-tim-3 antibodies | |
| HK40037072B (en) | Fc binding fragments comprising a pd-l1 antigen-binding site | |
| HK40037072A (en) | Fc binding fragments comprising a pd-l1 antigen-binding site |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |